Pharmacokinetics of CAMPATH-1H in BMT patients

Cytotherapy

Volumn 3, Issue 4, 2001, Pages 261-267

  Rebello, P ^a   Cwynarski, K ^b   Varughese, M ^b   Eades, A ^b   Apperley, J F ^b   Hale, G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bone marrow; CAMPATH; CD52; Half life; Pharmacokinetics; Stem cell; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAMPATH 1G; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; B CELL LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE RECIRCULATION; MALE; OPSONIZATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; STEM CELL TRANSPLANTATION; TREATMENT PLANNING; WHOLE BODY RADIATION;

EID: 0035555519     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532401317070899     Document Type: Article

References (18)

1. CD52 antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
2. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
3. CAMPATH-1 antibodies in stem-cell transplantation
4. CAMPATH-1 monoclonal antibodies in bone marrow transplantation
5. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-CAMPATH conditioning: An effective regimen with low procedure related toxicity
6. Reshaping human antibodies for therapy
7. Serum levels of CAMPATH-1H in recipients of unrelated bone marrow transplants
8. CMV serostatus is a major determinant of outcome after T depleted unrelated donor transplant in patients with chronic myeloid leukaemia; The case for tailored GVHD prophylaxis
9. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
10. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein
11. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials
12. Bone marrow transplantation for chronic myeloid leukaemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA Class I identity between donor and recipient
13. Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy and the monoclonal antibody CAMPATH-1G using limiting dilution methodology
14. Metabolic properties of IgG subclasses in man
15. Screening for basiliximab exposure-response relationships in renal allotransplantation
16. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study
17. Immune reconstitution after allogenic bone marrow transplantation depleted of T cells
18. CAMPATH-1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients